BROWSE

Related Scientist

Koh, Gou Young's photo.

Koh, Gou Young
혈관 연구단
more info

ITEM VIEW & DOWNLOAD

Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye

Cited 0 time in webofscience Cited 0 time in scopus
13 Viewed 0 Downloaded
Title
Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye
Author(s)
Gou Young Koh; Augustin, Hellmut G.; Campochiaro, Peter A.
Publication Date
2022-05
Journal
Trends in Molecular Medicine, v.28, no.5, pp.347 - 349
Publisher
Elsevier Ltd
Abstract
© 2022 Elsevier LtdFaricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.
URI
https://pr.ibs.re.kr/handle/8788114/11952
DOI
10.1016/j.molmed.2022.03.004
ISSN
1471-4914
Appears in Collections:
Center for Vascular Research(혈관 연구단) > 1. Journal Papers (저널논문)
Files in This Item:
There are no files associated with this item.

qrcode

  • facebook

    twitter

  • Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse